45
Publications
Links to access each publication and its plain language summary can be found by clicking "Read more"
Want to stay up to date on news from REPRIEVE?
Click here to sign up for the REPRIEVE Insights Newsletter!
October 11, 2024
Abstract Background: Among people with HIV (PWH), COVID-19 is common and potentially severe. We leveraged REPRIEVE to assess the effects of statin therapy for cardiovascular disease […]
October 8, 2024
Abstract Background: REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to […]
October 7, 2024
Abstract Objectives: To determine baseline prevalence of proteinuria and albuminuria among REPRIEVE participants and evaluate associated risk factors. Design: Cross sectional analysis of a baseline sample of participants […]
August 28, 2024
Abstract Background: Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods: REPRIEVE was a double-blind randomized controlled […]
August 28, 2024
Abstract Background Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives The purpose of this study was […]
May 2, 2024
Abstract The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) (Aug. 24 issue of NEJM) was a global trial that assessed pitavastatin calcium as compared […]
May 2, 2024
Abstract Background People with HIV (PWH) have a high burden of coronary plaques; however, the comparison to people without known HIV (PwoH) needs clarification. Objectives The […]
April 4, 2024
Abstract Background Coronary artery disease (CAD) is a leading cause of death among the 38.4 million people with HIV globally. The extent to which cardiovascular polygenic risk […]
February 21, 2024
Abstract Importance Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular […]
January 12, 2024
Abstract Key Points Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. […]
January 8, 2024
Abstract Background Cytomegalovirus (CMV) seropositivity is associated with poor outcomes, including physical function impairment, in people without HIV. We examined associations between CMV IgG titer and […]
September 28, 2023
Abstract Plasma VEGF coreceptor neuropilin-1 (NRP-1) had the largest association with coronary plaque in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) proteomics analysis. […]
July 31, 2023
Abstract Background Hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD), is common among people with HIV (PWH). We present baseline steatosis prevalence and cardiometabolic characteristics among […]
July 23, 2023
Abstract Background The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV), so data regarding primary prevention strategies in this population are […]
July 17, 2023
Abstract Background Pericoronary adipose tissue (PCAT) may influence plaque development through inflammatory mechanisms. We assessed PCAT density, as a measure of pericoronary inflammation, in relationship to […]
July 10, 2023
Abstract Objective Skeletal muscle quality and mass are important for maintaining physical function during advancing age. We leveraged baseline data from REPRIEVE to evaluate whether paraspinal muscle density […]
April 5, 2023
Abstract Background Mechanisms contributing to COVID-19 severity in people with HIV (PWH) are poorly understood. We evaluated temporal changes in plasma proteins following SARS-CoV-2 infection and […]
March 1, 2023
Abstract Inflammasome activation is increased in people with HIV (PWH), but its relationship with coronary plaque is poorly understood in this setting. In a large HIV […]
February 27, 2023
Abstract Weight gain with longer-term INSTI-based regimens remains unknown. Over 2-years of follow-up in REPRIEVE, INSTI use was associated with weight gain among those on an […]
February 27, 2023
Abstract People with HIV (PWH) appear at higher risk for suboptimal pathogen responses and worse COVID-19 outcomes, but the effects of host factors and COVID-19 on […]
November 30, 2022
Abstract Background REPRIEVE, the Randomized Trial to Prevent Vascular Events in HIV, is a multicenter, primary prevention trial evaluating whether a statin can prevent major cardiovascular […]
November 30, 2022
Abstract Objective To investigate relationships between Life’s Simple 7 (LS7), an assessment of cardiovascular health (CVH), and coronary plaque among people with HIV (PWH). Methods Coronary […]
September 27, 2022
Abstract Background Among people with HIV (PWH), sex-differences in presentations of atherosclerotic cardiovascular disease (ASCVD) may be influenced by differences in coronary plaque parameters, immune/inflammatory biomarkers, […]
September 1, 2022
Abstract Background Cytomegalovirus (CMV) infection is thought to result in increased immune activation in people with human immunodeficiency virus (HIV, PWH). Although some data have linked […]
August 11, 2022
Abstract Objective To characterize diet quality across a global cohort of people with HIV (PWH). Design Cross-sectional analysis. Methods Leveraging REPRIEVE data from baseline across five Global Burden […]
June 3, 2022
Abstract Background People with HIV (PWH) have subclinical coronary artery disease (CAD) despite low traditional atherosclerotic cardiovascular disease (ASCVD) risk scores. Coronary plaque in PWH presents […]
June 3, 2022
Abstract Background Limited data are available regarding asymptomatic COVID-19 among people with HIV (PWH). Data on a representative subset of PWH enrolled in REPRIEVE, a global clinical trial […]
March 7, 2022
Abstract Background We sought to explore multinational differences in functional status by Global Burden of Disease (GBD) regions in the REPRIEVE cohort. Methods REPRIEVE is a […]
March 3, 2022
Abstract Background Among ART-treated people with HIV (PWH), persistent systemic immune activation contributes to atherogenesis, cardiovascular disease (CVD) events, and mortality. Factors associated with key immune […]
December 13, 2021
Abstract Background People with HIV (PWH) are at increased risk for cardiovasvular disease (CVD) and sudden cardiac death. Prior work has suggested an association between HIV […]
December 13, 2021
Abstract Little is known regarding COVID-19 vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates […]
December 13, 2021
Abstract Background Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of […]
July 7, 2021
Abstract Background In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and HIV-related factors may contribute to future CV events in persons with HIV […]
July 7, 2021
Key Points Question What is the extent of coronary artery disease among people with well-controlled HIV and low to moderate risk of atherosclerotic cardiovascular disease (ASCVD), and […]
September 17, 2020
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 […]
September 17, 2020
Background: Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described. Methods: The REPRIEVE trial (Randomized Trial to […]
September 17, 2020
Background: Reproductive aging may contribute to cardiometabolic comorbid conditions. We integrated data on gynecologic history with levels of an ovarian reserve marker (anti-müllerian hormone [AMH)] to […]
September 17, 2020
Abstract: Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are under-reported in HIV and cardiovascular […]
September 17, 2020
Background: Chronic kidney disease is a common comorbid condition among persons living with human immunodeficiency virus (PWH). We characterized baseline kidney function in the REPRIEVE (Randomized […]
September 17, 2020
Background: People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, […]
September 17, 2020
Background: People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart […]
September 17, 2020
Background: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin medication can prevent […]
September 17, 2020
Background: Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need […]
September 17, 2020
Background: The REPRIEVE Mechanistic Substudy (A5333s) represents the first large, randomized, CCTA-based assessment of the effects of a primary prevention strategy for CVD on high-risk CAD, […]
December 15, 2017
Background: Women’s under-representation in HIV and cardiovascular disease (CVD) research suggests a need for novel strategies to ensure robust representation of women in HIV-associated CVD research. […]